Search: onr:"swepub:oai:DiVA.org:liu-23758" >
Serum disposition o...
-
Reis, MargaretaLund University,Lunds universitet,Linköpings universitet,Klinisk farmakologi,Hälsouniversitetet,Avdelningen för klinisk kemi och farmakologi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Chemistry and Pharmacology,Department of Laboratory Medicine,Faculty of Medicine
(author)
Serum disposition of sertraline, N-desmethylsertraline and paroxetine : a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression
- Article/chapterEnglish2004
Publisher, publication year, extent ...
-
2004-07-08
-
Wiley,2004
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-23758
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-23758URI
-
https://doi.org/10.1002/hup.599DOI
-
https://lup.lub.lu.se/record/272473URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1948946URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Sertraline and paroxetine are frequently prescribed SSRIs for long-term treatment of major depression. Nevertheless, continuous follow-ups of drug concentrations prevailing in patients during the whole treatment period are not available. Hence, in a large phase IV clinical trial, a total of 353 patients with major depression were enrolled for a 6-month comparison of sertraline (50–150 mg daily) and paroxetine (20–60 mg daily). The present study reports the pharmacokinetic results of up to eight serum samples per patient.1 A profound variability was found in the interindividual steady state and trough serum levels of sertraline, desmethylsertraline and paroxetine: the coefficient of variation (CV) was 59% for sertraline, 51% for desmethylsertraline, 27% for the ratio desmethylsertraline/sertraline (50 mg/day), and 71% for paroxetine (20 mg/day). The intraindividual CV for the ratio desmethylsertraline/sertraline was only 19%, indicating intraindividual metabolizing stability over time. Both sertraline and paroxetine displayed sex differences in the dose-concentration correlation.2 It was possible to predict sertraline, but not paroxetine, steady state levels.3 The terminal elimination t½ for both drugs after 6 months of treatments was similar to data previously reported from short-term withdrawal studies.4 No correlation between serum drug concentrations and clinical effect was detected for either sertraline or paroxetine.For the future, continuous efforts are warranted to perform PK investigations in the natural clinical setting in which the drugs are usually prescribed.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Åberg-Wistedt, AnnaInstitute of Clinical Neuroscience, Department of Psychiatry, Karolinska Institute, Stockholm, Sweden
(author)
-
Ågren, HansKarolinska Institute, Neurotec, Department Division of Psychiatry, Huddinge University Hospital, Huddinge, Sweden
(author)
-
Höglund, PeterLund University,Lunds universitet,Avdelningen för klinisk kemi och farmakologi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Chemistry and Pharmacology,Department of Laboratory Medicine,Faculty of Medicine,Institute of Laboratory Medicine, Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden(Swepub:lu)kfar-pho
(author)
-
Åkerblad, Ann-CharlotteDepartment of Neuroscience, Psychiatry, Uppsala University Hospital, Uppsala University, Uppsala, Sweden
(author)
-
Bengtsson, Finn,1956-Department of Neuroscience, Psychiatry, Uppsala University Hospital, Uppsala University, Uppsala, Sweden(Swepub:liu)finbe20
(author)
-
Linköpings universitetKlinisk farmakologi
(creator_code:org_t)
Related titles
-
In:Human Psychopharmacology: Wiley19:5, s. 283-2910885-62221099-1077
Internet link
Find in a library
To the university's database